Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Ningetinib

Catalog No: tcsc0027542

Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
1394820-69-9

Formula:
$C_{31}H_{29}FN_4O_5$

Pathway:
Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK

Target:
c-Met/HGFR;VEGFR;TAM Receptor

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Observed Molecular Weight:
556.58

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (**TKI**) with **IC_{50}**s of 6.7, 1.9 and c-Met, **VEGFR2** and **Axl**, respectively.

IC50 & Target: VEGFR, c-Met, and Axl[1]

In Vitro: Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC_{50}s of 6.7, 1.9 and 50 values of 8.6 and 6.3 nM, respectively[1].

In Vivo: When single dosed orally (3 mg/kg) to U87MG tumor-bearing nude mice, Ningetinib (CT053PTSA) potently inhibits the phosphorylation of c-Met and its downstream signaling kinases AKT and ERK1/2 for up to 6 hours in tumor tissues. In orthotopic U87MG human glioblastoma xenograft model, Ningetinib prolongs the median survival time (MST) and yields significant increase in life-span value (ILS=32%, p=0.003) at an oral dose of 20 mg/kg/day (dosed 21 days) versus the vehicle-treated group[1].